Canopy Growth (CGC) Projected to Post Quarterly Earnings on Friday

Canopy Growth (NASDAQ:CGC) is projected to release its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect Canopy Growth to post earnings of ($0.03) per share and revenue of $70.9570 million for the quarter. Investors can check the company’s upcoming Q3 2026 earning summary page for the latest details on the call scheduled for Friday, February 6, 2026 at 10:00 AM ET.

Canopy Growth (NASDAQ:CGC) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. Canopy Growth had a negative return on equity of 61.97% and a negative net margin of 113.21%.The firm had revenue of $47.86 million for the quarter, compared to analyst estimates of $71.82 million. On average, analysts expect Canopy Growth to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Canopy Growth Stock Down 2.6%

Shares of NASDAQ CGC opened at $1.11 on Friday. The stock has a market capitalization of $408.99 million, a P/E ratio of -0.57 and a beta of 0.43. The stock’s fifty day moving average is $1.25 and its 200 day moving average is $1.29. Canopy Growth has a 52 week low of $0.77 and a 52 week high of $2.90. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.23 and a current ratio of 5.50.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Benchmark raised Canopy Growth from a “sell” rating to a “hold” rating in a research note on Monday, November 10th. Alliance Global Partners restated a “neutral” rating on shares of Canopy Growth in a report on Monday, December 15th. Wall Street Zen upgraded shares of Canopy Growth from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Canopy Growth in a research report on Wednesday, January 21st. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Institutional Investors Weigh In On Canopy Growth

A number of institutional investors and hedge funds have recently modified their holdings of the company. Two Sigma Investments LP bought a new stake in Canopy Growth in the 3rd quarter worth $1,767,000. UBS Group AG boosted its position in Canopy Growth by 32.1% during the 3rd quarter. UBS Group AG now owns 575,107 shares of the company’s stock valued at $840,000 after acquiring an additional 139,725 shares in the last quarter. Mackenzie Financial Corp grew its stake in Canopy Growth by 33.1% in the third quarter. Mackenzie Financial Corp now owns 111,945 shares of the company’s stock worth $163,000 after purchasing an additional 27,823 shares during the period. Two Sigma Securities LLC grew its position in shares of Canopy Growth by 4.4% in the 2nd quarter. Two Sigma Securities LLC now owns 280,852 shares of the company’s stock worth $343,000 after buying an additional 11,942 shares during the period. Finally, Murchinson Ltd. bought a new position in shares of Canopy Growth during the second quarter valued at approximately $183,000. 3.33% of the stock is owned by hedge funds and other institutional investors.

Canopy Growth Company Profile

Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.

The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.